Calgary, Alberta, Canada July 9,  2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to highlight the recently published paper “Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice” by a member of its scientific advisory board, Dr. David Blum and colleagues (PMID 3896478).

In this study, published in the leading neurological journal “Brain”, Dr. Blum and colleagues reported that early increases of the adenosine A2A receptor (A2aRs) in brain cells (neurons), can lead to the development of memory loss in mouse models of Alzheimer’s. What was notable in this study, was that the memory deficits and behaviour changes in transgenic (APP/PS1) mice were linked to Tau phosphorylation (specifically at the AT8 site), rather than amyloid plaques (the conventional Alzheimer’s target).

 “The data seems to back up the expression that in Alzheimer’s Disease (AD), beta amyloid is the trigger and Tau is the bullet” said Dr. Mark Williams, CSO of Marvel. In recent news, Marvel reported that its lead asset MB204, an A2aR antagonist (which acts against the receptor), decreased Tau phosphorylation (including the AT8 site) in an acute oral study. The mechanism(s) by which MB204 reduces Tau phosphorylation are currently being investigated with Professor Emmanuel Planel, a world leading expert on Tau pathology. Overall, the body of evidence suggests that orally available A2aR antagonists such as MB204 could be a valuable new approach to reducing Tau pathology and treating Alzheimer’s cognitive deficits.


About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.


Contact Information

 Marvel Biosciences Corp.

J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

 All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.

 This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations. 

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.